UK Markets closed
NIKKEI 225
27,685.47 -8.18 (-0.03%) HANG SENG
21,298.70 +76.54 (+0.36%) CRUDE OIL
77.59 +3.48 (+4.70%) GOLD FUTURES
1,885.10 +5.60 (+0.30%) DOW
34,156.69 +265.67 (+0.78%) BTC-GBP
19,284.53 +191.82 (+1.00%)
Akebia Therapeutics, Inc. (AKBA)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 1.0700 |
| Open | 1.1000 |
| Bid | 1.1100 x 1300 |
| Ask | 1.1300 x 1200 |
| Day's range | 0.9915 - 1.1400 |
| 52-week range | 0.2410 - 2.9300 |
| Volume | |
| Avg. volume | 1,947,919 |
| Market cap | 207.877M |
| Beta (5Y monthly) | 1.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.7690 |
| Earnings date | 27 Feb 2023 - 03 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.63 |
- Simply Wall St.
Akebia Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags
Akebia Therapeutics ( NASDAQ:AKBA ) Third Quarter 2022 Results Key Financial Results Revenue: US$49.0m (flat on 3Q...
- Zacks
Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -86.67% and 3.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Akebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 174.19% and 158.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
© 2023 Yahoo. All rights reserved.
